title: Clinical features and outcome in HCV-positive aggressive non-Hodgkin's lymphoma.
abstract: The clinical features and outcome of 25 previously untreated aggressive non-Hodgidn's lymphoma (NHL) patients with hepatitis C virus (HCV) infection were evaluated retrospectively. The patients included 18 males and 7 females with a median age of 66 years. The median observation period for survivors was 32 months. Although there were no patients with hepatocellular carcinoma during the follow-up period, 7 patients had cirrhosis (LC) at the initiation of therapy for NHL. Seventeen patients (68%) had initial extranodal involvement including 2 cases with liver involvement. The 5-year overall survival (OS) rate in the whole group was 46%, and the 5-year relapse-free survival (RFS) rate of patients with complete response (CR) was 48%. Patients with non-cirrhosis (n = 18) showed better OS (P = 0.04) compared with patients with LC (n = 7) and 5-year OS rates were 55 and 21%, respectively. Fourteen patients died in the whole group; 4 of NHL and 2 of liver failure in the LC group and 8 of NHL in the non-cirrhotic group. Among the latter 8 patients, cumulative dose (CD) of doxorubicin (ADR) and cyclophosphamide (CPA) were significantly lower than those of survivors with non-cirrhosis. In conclusion, patients with HCV-positive aggressive NHL have a similar prognosis as HCV-negative aggressive NHL. In non-cirrhotic patients, attention should be paid to the CD of drugs required to cure the aggressive NHL.
authors.affiliation: First Department of Internal Medicine, Yokohama City University School of Medicine, Japan. cavalier@ch-yamate.dlenet.com
authors.forename: Naoto
authors.initials: N
authors.lastname: Tomita
authors.forename: Fumio
authors.initials: F
authors.lastname: Kodama
authors.forename: Maki
authors.initials: M
authors.lastname: Takabayashi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kawano
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamaji
authors.forename: Katsumichi
authors.initials: K
authors.lastname: Fujimaki
authors.forename: Shin
authors.initials: S
authors.lastname: Fujisawa
authors.forename: Heiwa
authors.initials: H
authors.lastname: Kanamori
authors.forename: Shigeki
authors.initials: S
authors.lastname: Motomura
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ishigatsubo
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D016174:Hepacivirus / Q000378:metabolism; D006526:Hepatitis C / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide